EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

A systematic review and meta-analysis of shRNA–IL-6-engineered CAR-T cells for B-cell acute lymphoblastic leukemia: a stepping stone toward risk-free immunotherapy

Mohamed S Attia, Brett Dyer, Nigel McMillan, Matthew Zunk iD

Bioscience Reports · 17.06.2026 · 46 (6)

DOI: 10.1042/bsr20260143 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Bioscience Reports, online erschienen am 22.05.2026. Verfasst von Mohamed S Attia und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Medical Science, Griffith University, Southport 4215, Queensland, Australia. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Interleukin-6, Receptors, Chimeric Antigen, RNA, Small Interfering. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PhD support from Griffith University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical application of chimeric antigen receptor (CAR)-T cells, especially those targeting CD19, stands as a breakthrough in treating relapsed or refractory B-cell acute lymphoblastic leukemia. Yet, preventing immune-related adverse events, like severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), remains a significant concern. This meta-analysis looked at the efficacy and safety of interleukin-6 knockdown CAR-T therapy. The study’s primary outcomes included the incidence of CRS, ICANS, and the number of patients achieving an early complete response (CR) and overall response (OR) rates at one-month post-infusion of anti-CD19 shRNA-engineered CAR-T cells. The random-effects model was used to estimate summary effects. Certainty of evidence was assessed using GRADE. Out of 275 studies screened, 7 studies were eligible (n = 178 patients). The pooled OR and CR rates were 88% (95% CI: 81–92) and 84% (95% CI: 78–89), respectively, with no heterogeneity detected. Among 147 patients, 116 (78%, 95% CI: 68–85) developed CRS, whereas 46 (28%, CI: 21%–35%) out of 178 were affected by severe grades (≥3). While ICANS was detected in 13 out of 159 patients (13%, CI: 2%–51%, I2 = 69.5%), three studies confirmed the absence of severe grade ICANS. According to GRADE assessment, current analysis presents low certainty of evidence supporting investigated outcomes, except for ICANS (any grade) that was deemed very low. More importantly, as all included studies were conducted in China, the findings may not be readily generalizable to other healthcare systems and ethnically diverse populations. Therefore, our confidence in the effect estimates is limited and it may vary from true estimates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveInterleukin-6Receptors, Chimeric AntigenRNA, Small InterferingPrecursor B-Cell Lymphoblastic Leukemia-LymphomaT-LymphocytesHumansAntigens, CD19Cytokine Release SyndromeTreatment Outcome

Stichwörter der Autor:innen

CAR T therapyCD19Cytokine release syndromeimmune-related adverse effects

Substanzen

Interleukin-6Receptors, Chimeric AntigenAntigens, CD19RNA, Small InterferingIL6 protein, humanCD19 molecule, human

Autor:innen und Institutionen

  • School of Pharmacy and Medical Science, Griffith University, Southport 4215, Queensland, Australia.
  • Griffith Biostatistics Unit, Griffith Health, Griffith University, Southport 4215, Queensland, Australia.
  • Institute for Biomedicine and Glycomics, Griffith University, Southport 4215, Queensland, Australia.

ORCID-Profile: Matthew Zunk

Förderung

  • PhD support from Griffith University

Zitieren

APA

Attia, M. S., Dyer, B., McMillan, N., & Zunk, M. (2026). A systematic review and meta-analysis of shRNA–IL-6-engineered CAR-T cells for B-cell acute lymphoblastic leukemia: a stepping stone toward risk-free immunotherapy. Bioscience Reports, 46(6). https://doi.org/10.1042/bsr20260143

Vancouver

Attia MS, Dyer B, McMillan N, Zunk M. A systematic review and meta-analysis of shRNA–IL-6-engineered CAR-T cells for B-cell acute lymphoblastic leukemia: a stepping stone toward risk-free immunotherapy. Bioscience Reports. 2026;46(6). doi:10.1042/bsr20260143

BibTeX
@article{Attia2026,
  author = {Attia, Mohamed S and Dyer, Brett and McMillan, Nigel and Zunk, Matthew},
  title = {A systematic review and meta-analysis of shRNA–IL-6-engineered CAR-T cells for B-cell acute lymphoblastic leukemia: a stepping stone toward risk-free immunotherapy},
  journal = {Bioscience Reports},
  year = {2026},
  volume = {46},
  number = {6},
  doi = {10.1042/bsr20260143}
}
Kostenlos starten →